Table 1.

Baseline (prior to durvalumab therapy) clinical and demographic characteristics of the 71 patients who have high-quality TCR sequencing data in either time points

Characteristic	Number of patients (N = 71)
Male sex—no. (%)	39 (54.9)
Age ≥ 65 years—no. (%)	36 (50.7)
Squamous histology—no. (%)	37 (52.1)
Caucasian race—no. (%)	71 (100)
PD-L1 low/negative—no. (%)	20 (29.0)
ECOG score of 1 at baseline—no. (%)	45 (63.4)
Smoking history—no. (%)
Current	13 (18.3)
Former	53 (74.6)
Never	5 (7.0)
Prior line of therapy—no. (%)	21 (29.6)
Liver metastases at baseline—no. (%)	19 (27.5)
Response
Progressive disease	21 (29.6)
Stable disease	34 (47.9)
Response	16 (22.5)